Rheumatology · Plantation, FL
NPI
1245252402
Since 2006
Specialty
Rheumatology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
140 SW 84th Ave, Suite B
Plantation, FL, 33324
Phone (954) 476-2338
Groups this clinician bills Medicare through
Medicare paid, 2024
$292K
43,391 services
Medicare patients, 2024
385
Average age 73
Drug cost, 2024
$7.3M
3,488 prescriptions
Company payments, 2025
$186K
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Guillermo J Valenzuela was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 23,217 times for 16 patients. In total Guillermo J Valenzuela billed 43,391 services in 74 codes, and Medicare paid $292K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-26.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 23,217 | 16 | $2.99 | $69K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 4,231 | 73 | $0.10 | $437 |
| J0897 Injection, denosumab, 1 mg | Office | 2,235 | 39 | $14.06 | $31K |
| 99214 Office E&M - Established | Office | 805 | 333 | $90.38 | $73K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 257 | 181 | $12.91 | $3,318 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 189 | 63 | $0.44 | $84.01 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 184 | 22 | $0.73 | $135 |
| 96401 Chemotherapy Administration | Office | 144 | 28 | $55.43 | $7,981 |
| 20611 Joint Injection | Office | 139 | 54 | $85.32 | $12K |
| 96413 Chemotherapy Administration | Office | 131 | 29 | $94.97 | $12K |
| 96372 Injection Administration | Office | 112 | 55 | $10.31 | $1,155 |
| 20551 Musculoskeletal | Office | 78 | 54 | $41.44 | $3,232 |
| 99204 Office E&M - New | Office | 77 | 77 | $124.41 | $9,579 |
| 77085 Standard X-ray | Office | 75 | 74 | $52.64 | $3,948 |
| 96415 Chemotherapy Administration | Office | 72 | 24 | $21.46 | $1,545 |
By year: 2022 $1.0M for 85,867 services; 2023 $398K for 24,625 services; 2024 $292K for 43,391 services.
Medicare prescription drug claims, 2024
In 2024, the drug Guillermo J Valenzuela prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 422 prescriptions and refills. In total Guillermo J Valenzuela wrote 3,488 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 422 | 748 | 141 | $6,420 |
| Prednisone Generic | 310 | 443 | 102 | $1,734 |
| Hydroxychloroquine Sulfate Generic | 293 | 523 | 108 | $6,145 |
| Prolia Denosumab | 273 | 1,629 | 192 | $477K |
| Benlysta Belimumab | 149 | 149 | 15 | $642K |
| Actemra Tocilizumab | 142 | 142 | 17 | $375K |
| Orencia Abatacept/Maltose | 129 | 129 | 19 | $575K |
| Folic Acid Generic | 123 | 235 | 51 | $446 |
| Remicade Infliximab | 115 | 166 | 24 | $605K |
| Alendronate Sodium Generic | 111 | 274 | 48 | $709 |
| Meloxicam Generic | 82 | 136 | 34 | $224 |
| Allopurinol Generic | 74 | 178 | 25 | $671 |
| Inflectra Infliximab-Dyyb | 66 | 92 | 16 | $244K |
| Evenity (2 Syringes) Romosozumab-Aqqg | 64 | 64 | 16 | $155K |
| Cimzia (2 Pack) Certolizumab Pegol | 63 | 65 | Under 11 | $410K |
Brand drugs: - claims; generic drugs: 2,001 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Guillermo J Valenzuela $186K ($186K in general payments such as food, travel and fees) from 32 companies. The largest payer was UCB, Inc. with $44K.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 69 | $44K |
| Genzyme Corporation SNY | 33 | $40K |
| GlaxoSmithKline, LLC. GSK | 21 | $22K |
| Janssen Biotech, Inc. JNJ | 18 | $16K |
| Amgen Inc. AMGN | 40 | $13K |
| Abbvie Inc. ABBV | 26 | $11K |
| Novartis Pharmaceuticals Corporation NVS | 17 | $10K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 11 | $8,781 |
| Mylan Inc. | 2 | $6,086 |
| Idorsia Pharmaceuticals US Inc | 1 | $5,000 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.